Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.13
GENE's Cash to Debt is ranked lower than
66% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. GENE: 1.13 )
Ranked among companies with meaningful Cash to Debt only.
GENE' s 10-Year Cash to Debt Range
Min: 1.13  Med: 25.44 Max: No Debt
Current: 1.13
Equity to Asset 0.27
GENE's Equity to Asset is ranked lower than
88% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. GENE: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
GENE' s 10-Year Equity to Asset Range
Min: 0.27  Med: 0.78 Max: 0.88
Current: 0.27
0.27
0.88
F-Score: 2
Z-Score: -19.48
M-Score: 1.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -203.82
GENE's Operating margin (%) is ranked lower than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. GENE: -203.82 )
Ranked among companies with meaningful Operating margin (%) only.
GENE' s 10-Year Operating margin (%) Range
Min: -313.93  Med: -77.58 Max: 5.73
Current: -203.82
-313.93
5.73
Net-margin (%) -207.89
GENE's Net-margin (%) is ranked lower than
80% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. GENE: -207.89 )
Ranked among companies with meaningful Net-margin (%) only.
GENE' s 10-Year Net-margin (%) Range
Min: -496.89  Med: -77.45 Max: 4.98
Current: -207.89
-496.89
4.98
ROE (%) -396.12
GENE's ROE (%) is ranked lower than
96% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. GENE: -396.12 )
Ranked among companies with meaningful ROE (%) only.
GENE' s 10-Year ROE (%) Range
Min: -271.23  Med: -48.01 Max: 14.99
Current: -396.12
-271.23
14.99
ROA (%) -196.52
GENE's ROA (%) is ranked lower than
95% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. GENE: -196.52 )
Ranked among companies with meaningful ROA (%) only.
GENE' s 10-Year ROA (%) Range
Min: -134.56  Med: -39.49 Max: 10.58
Current: -196.52
-134.56
10.58
ROC (Joel Greenblatt) (%) -3518.12
GENE's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. GENE: -3518.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GENE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2298.65  Med: -343.21 Max: 67.19
Current: -3518.12
-2298.65
67.19
Revenue Growth (3Y)(%) -41.50
GENE's Revenue Growth (3Y)(%) is ranked lower than
91% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. GENE: -41.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GENE' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 58.7
Current: -41.5
0
58.7
» GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GENE Guru Trades in Q2 2014

Jim Simons 18,000 sh (New)
» More
Q3 2014

GENE Guru Trades in Q3 2014

Jim Simons 108,800 sh (+504.44%)
» More
Q4 2014

GENE Guru Trades in Q4 2014

Jim Simons 294,000 sh (+170.22%)
» More
Q1 2015

GENE Guru Trades in Q1 2015

Jim Simons 650,780 sh (+1006.77%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 2.96
GENE's P/S is ranked lower than
51% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. GENE: 2.96 )
Ranked among companies with meaningful P/S only.
GENE' s 10-Year P/S Range
Min: 0.88  Med: 3.60 Max: 19.17
Current: 2.96
0.88
19.17
Current Ratio 1.88
GENE's Current Ratio is ranked lower than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. GENE: 1.88 )
Ranked among companies with meaningful Current Ratio only.
GENE' s 10-Year Current Ratio Range
Min: 1.08  Med: 3.17 Max: 5.22
Current: 1.88
1.08
5.22
Quick Ratio 1.79
GENE's Quick Ratio is ranked lower than
60% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. GENE: 1.79 )
Ranked among companies with meaningful Quick Ratio only.
GENE' s 10-Year Quick Ratio Range
Min: 0.99  Med: 3.09 Max: 5.22
Current: 1.79
0.99
5.22
Days Inventory 33.05
GENE's Days Inventory is ranked higher than
72% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. GENE: 33.05 )
Ranked among companies with meaningful Days Inventory only.
GENE' s 10-Year Days Inventory Range
Min: 20.08  Med: 31.24 Max: 42.4
Current: 33.05
20.08
42.4
Days Sales Outstanding 68.89
GENE's Days Sales Outstanding is ranked lower than
54% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. GENE: 68.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
GENE' s 10-Year Days Sales Outstanding Range
Min: 8.08  Med: 20.63 Max: 58.92
Current: 68.89
8.08
58.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.87
GENE's Price/Median PS Value is ranked higher than
76% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. GENE: 0.87 )
Ranked among companies with meaningful Price/Median PS Value only.
GENE' s 10-Year Price/Median PS Value Range
Min: 0.41  Med: 2.18 Max: 15.25
Current: 0.87
0.41
15.25
Earnings Yield (Greenblatt) (%) -41.96
GENE's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. GENE: -41.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GENE' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -41.96  Med: 2.20 Max: 1804.9
Current: -41.96
-41.96
1804.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:GTG.Australia, GNTLF.USA, DU8.Germany,
Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
» More Articles for GENE

Headlines

Articles On GuruFocus.com
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication Ini Jul 14 2015 
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015 
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014 
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 15 2014 
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 15 2014 

More From Other Websites
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication... Jul 14 2015
Genetic Technologies Announces Appointment of Chief Financial Officer Jun 15 2015
PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING... May 28 2015
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST... May 11 2015
Shires Earnings Just Made The Best Drug Reformulation Story Even Better May 01 2015
Genetic Technologies Drives Ahead in the Fight Against Cancer Apr 20 2015
Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test Apr 20 2015
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R) Apr 20 2015
These 5 Stocks Have More Than Doubled In 2015 Apr 06 2015
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015
The Trade Traders are Waiting for in Genetic Technologies ($GENE) Feb 19 2015
Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R) Jan 29 2015
Genetic Technologies Secures A$24 Million Standby Equity Placement Facility Jan 21 2015
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014
GENETIC TECHNOLOGIES LTD Financials Nov 04 2014
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 06 2014
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 01 2014
Genetic Technologies Announces Appointment of Independent Non-Executive Directors Sep 24 2014
Genetic Technologies Announces Divestment of Australian Based Heritage Business Sep 22 2014
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of... Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK